Table 2:

Patient safety and efficacy outcomes

	No tirofiban (n = 279)	Tirofiban (n = 35)	Unadjusted	Adjusted^{^a}	P value
	No tirofiban (n = 279)	Tirofiban (n = 35)	OR (95% CI)	OR (95% CI)	Unadjusted/Adjusted^{^a}
Successful reperfusion	210 (75.3%)	28 (80.0%)	1.31 (0.57−3.38)	1.56 (0.53 to 5.34)	.684/.440
Postprocedural reocclusion^{^b}	11 (4.4%)	1 (2.9%)	0.65 (0.03−3.52)	0.19 (0.01−1.30)	.688/.151
3-month good outcome	150 (53.8%)	20 (57.1%)	1.14 (0.56−2.36)	2.22 (0.89−6.12)	.843/.099
3-month death	35 (12.5%)	2 (5.7%)	0.42 (0.06−1.47)	0.38 (0.04−1.87)	.366/.299
Serious hemorrhage	31 (11.1%)	3 (8.6%)	0.75 (0.17−2.25)	1.07 (0.20−4.10)	.867/.918
IVH	19 (6.8%)	1 (2.9%)	0.04 (0.02−2.03)	0.43 (0.02−2.85)	.592/.467

Note:—IVH indicates intraventricular hemorrhage; OR, Odds ratio.
↵a Adjusted for sex, intraprocedural reocclusion, intracranial stenting, etiology of large vessel occlusion.
↵b Postprocedural reocclusion was assessed in 248 patients (no tirofiban group) and in 34 patients (tirofiban group).